Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
Open Access
- 28 October 2024
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-6
Abstract
Patients with HER2(+) early breast cancer (EBC) receiving neoadjuvant systemic therapy (NAST) have poorer outcomes if they have residual disease (RD). We analyzed IDFS and brain metastasis (BM) rates in patients with HER2(+) EBC treated with NAST and report the outcomes of patients with HER2(−) RD. Patients with HER2(+) EBC who received NAST between 1 Jan 2019 and 31 Jan 2022 were reviewed. IDFS was defined as the time from surgery until first occurrence of invasive breast cancer recurrence, distant recurrence, or death from any cause. The total cohort was 594 patients. pCR (ypT0/isN0) was achieved in 325(55%) and RD was seen in 269(45%) patients. In 269 patients with RD, 45(17%) did not have HER2 retesting and were excluded. In the remaining 224 patients, 143(64%) were HER2(+) and 81(36%) were HER2(−). With a median follow up of 24 months, 8 patients developed BM at initial recurrence, 4/325(1.2%) with pCR and 4/143(2.8%) with HER2(+) RD. IDFS events occurred in 22/594(3%) patients; 14/269(5%) in RD and 8/325(2%) in pCR (p = 0.04). There was no difference in IDFS between 9/143(6%) patients with HER2(+) RD or 5/81(6%) with HER2(−) RD (p = 0.10). Patients with RD had higher IDFS events than those with pCR. In those with RD, 36% lost HER2(+) status; IDFS events appeared similar in those with HER2(+) RD versus those with HER2(−) RD. The BM events seen in those with RD and pCR highlights the need for more effective therapy in NAST and adjuvant setting to minimize BM risk.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancerCancer Medicine, 2023
- Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINEnpj Breast Cancer, 2022
- Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, CanadaJAMA Network Open, 2022
- Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialNature Medicine, 2022
- Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumabnpj Breast Cancer, 2022
- Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomesJournal of Surgical Oncology, 2021
- Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast CancerJAMA Oncology, 2021
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerNew England Journal of Medicine, 2019
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerNew England Journal of Medicine, 2017
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtypeBreast Cancer Research and Treatment, 2012